Johnson & Johnson sales are expected to reach $100B by 2025, driven by cancer and immune drugs, despite patent challenges.
Author: PharmaSignal News Desk
Valneva Chikungunya vaccine is withdrawn from the US market following FDA suspension, raising concerns about its future.
PharmaSignal Take The week’s events signal a continued trend of strategic acquisitions and regulatory advancements in the pharma sector. The takeover talks between Oxford Biomedica and EQT, and the acquisition of Ventyx by Lilly, stress-test the assumption of platform scalability and integration risk. These developments have significant implications for post-close decision-making, particularly in terms of asset integration and portfolio expansion. This week’s PharmaSignal Weekly Brief – Global Pharma Roundup highlights an uptick in M&A activity, regulatory advancements, and pipeline developments. The dominant themes include strategic acquisitions, FDA approvals, and promising pipeline projects. M&A and Strategic Deals Oxford Biomedica engages in…
Oxford Biomedica EQT talks highlight the biotech investor’s interest, despite previous rejections of bids deemed undervalued.
Lilly obesity pill orforglipron is under FDA review with a decision expected in Q2 2025, aiming to compete with Novo Nordisk’s offerings.
AbbVie invests $650 million in a dual-targeting immunotherapy from RemeGen, enhancing its oncology portfolio.
A senior BD execution signal from this month’s most instructive pharma deal.
PharmaSignal Take This week’s events signal a continued focus on M&A activity and regulatory approvals, with companies such as Lilly and BioMarin making strategic acquisitions, and Novo Nordisk and Cytokinetics gaining FDA approvals. These events stress test assumptions around execution readiness and regulatory optimism. In this week’s PharmaSignal Weekly Brief – Global Pharma Roundup, the dominant themes include M&A activity, regulatory approvals, and pipeline development. M&A and Strategic Deals Lilly’s $1.2B acquisition of Ventyx to target NLRP3 inflammasome signals a strategic move to expand its immunology portfolio. The deal structure and potential integration risks are worth noting. Read more →…
Insmed lung drug sales surpass expectations in Q1 2025, while J&J secures a US pricing deal.
Alveus obesity drug secures $160M to advance into Phase 2 testing, targeting amylin and GLP-1 pathways.